Wall Street analysts expect Lexeo Therapeutics to report a Q3 2026 consensus net loss of $0.34 per share on zero revenue, while the stock currently trades around $2.89 against a high-conviction $20.30 average price target.
Investors are primarily focused on the clinical progress and enrollment status of the SUNRISE-FA 2 pivotal trial for LX2006, the company's lead gene therapy candidate for Friedreich ataxia cardiomyopathy.
Recent regulatory milestones, including the FDA's RMAT designation for the LX2020 program in August, have strengthened the company's cardiovascular pipeline outlook.
Market participants will also scrutinize the company's cash burn and remaining runway, which was previously projected to fund operations into 2028 following a recent $300 million shelf registration.